Compare WVE & CNXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | CNXC |
|---|---|---|
| Founded | 2012 | 1991 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2015 | 2020 |
| Metric | WVE | CNXC |
|---|---|---|
| Price | $13.25 | $33.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | $30.87 | ★ $69.00 |
| AVG Volume (30 Days) | ★ 2.2M | 1.3M |
| Earning Date | 05-29-2026 | 04-15-2026 |
| Dividend Yield | N/A | ★ 4.10% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,704,000.00 | ★ $9,825,771,000.00 |
| Revenue This Year | N/A | $5.17 |
| Revenue Next Year | $119.93 | $2.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 149.43 | 2.15 |
| 52 Week Low | $5.28 | $29.35 |
| 52 Week High | $21.73 | $66.00 |
| Indicator | WVE | CNXC |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 48.83 |
| Support Level | $12.53 | $31.63 |
| Resistance Level | $14.56 | $44.40 |
| Average True Range (ATR) | 0.79 | 1.85 |
| MACD | -0.04 | 0.60 |
| Stochastic Oscillator | 26.10 | 81.68 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.